|
HS Code |
427050 |
| Chemical Formula | C10H13NO5 |
| Molar Mass | 227.215 g/mol |
| Physical State | Solid (likely, based on similar cyclic imide structures) |
| Solubility In Water | Low (hydrophobic due to cycloalkyl and cyclic imide groups) |
| Solubility In Organic Solvents | Soluble in common organic solvents like dichloromethane, chloroform (due to non - polar nature of the molecule) |
| Stability | Stable under normal conditions; may react with strong acids, bases or reducing/oxidizing agents |
As an accredited 1-{[(Cyclopentyloxy)Carbonyl]Oxy}Pyrrolidine-2,5-Dione factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | 100g of 1-{[(Cyclopentyloxy)Carbonyl]Oxy}Pyrrolidine - 2,5 - Dione in sealed chemical - grade packaging. |
| Shipping | The chemical 1-{[(Cyclopentyloxy)carbonyl]Oxy}Pyrrolidine - 2,5 - Dione is shipped in containers suitable for chemicals. Packing ensures stability. Shipment follows strict regulations to prevent spillage and ensure safe transportation. |
| Storage | 1 - {[(Cyclopentyloxy)Carbonyl]Oxy}Pyrrolidine - 2,5 - Dione should be stored in a cool, dry place, away from heat sources and direct sunlight. Keep it in a well - sealed container to prevent exposure to moisture and air, which could potentially lead to decomposition or degradation. Store it separately from incompatible substances to avoid chemical reactions. |
In Fmoc-based solid-phase peptide synthesis, the selective protection of the ε-amine of lysine residues without resorting to tert-butyloxycarbonyl (Boc) chemistry is achievable through the introduction of the cyclopentyloxycarbonyl (Cpc) group. The reagent 1-{[(cyclopentyloxy)carbonyl]oxy}pyrrolidine-2,5-dione (Cpc-OSu) delivers this group under mildly basic conditions, generating a carbamate linkage that remains intact during repeated piperidine-mediated Fmoc deprotection cycles yet cleaves cleanly upon treatment with a trifluoroacetic acid (TFA) cocktail whose acidolytic strength is tuned to avoid aspartimide rearrangement in acid-sensitive sequences. In a typical production campaign for a 9-mer peptide containing two Lys(Cpc) residues on a 100 mmol scale using a low-loading Wang resin (0.3 mmol/g), the acylation protocol employs 3.5 equivalents of Cpc-OSu relative to free ε-amine sites in a dimethylformamide (DMF) solution containing 0.1 M 1-hydroxybenzotriazole (HOBt) to suppress racemization. The slurry is agitated under nitrogen overlay in a jacketed solid-phase synthesis reactor (ChemGlass model CG-1949, L/D ratio 2.1, PTFE frit porosity 40–60 µm) at 18–22 °C for 45 minutes, with real-time Kaiser test monitoring (ninhydrin-based colorimetric threshold A570 ≤ 0.05) to confirm quantitative capping. The global release of the Cpc groups occurs during the final TFA/water/triisopropylsilane (95:2.5:2.5 v/v) cleavage for 2.5 h at 25 ± 1 °C, yielding the crude deprotected peptide that is precipitated in chilled methyl tert-butyl ether and isolated by centrifugation. The process complies with ICH Q7A for active pharmaceutical ingredient manufacturing, and the residual cyclopentanol content in the final lyophilized peptide is controlled below 500 ppm as per ICH Q3C(R8) Class 2 residual solvent limits, verified by headspace gas chromatography (USP<467>). The terminal products are custom peptides ranging from 8 to 40 residues destined as active pharmaceutical ingredients (APIs) for metabolic disorder therapeutics or as immunogenic peptide carriers for conjugate vaccine development, where the Cpc strategy provides orthogonal protection that circumvents the acidolytic instability of Boc groups during iterative coupling steps on sensitive Trp- and Met-containing sequences.What Differentiates Cpc from Alloc Protection in Continuous-Flow Peptide Assembly?The shift from batch solid-phase reactors to continuous-flow packed-bed columns operating at backpressures of 50–80 bar places stringent stability requirements on side-chain protecting groups that are exposed to transient thermal excursions during pump-induced shear heating. While allyloxycarbonyl (Alloc) removal relies on Pd(PPh₃)₄-catalyzed allyl transfer that introduces metal scavenging unit operations, the cyclopentyloxycarbonyl (Cpc) group installed via 1-{[(cyclopentyloxy)carbonyl]oxy}pyrrolidine-2,5-dione withstands all coupling and deprotection solvents encountered in an Fmoc flow cycle—namely DMF containing 20% piperidine at 80°C residence time 2 min—without premature cleavage. In a continuous-flow peptide synthesizer (Vapourtec R-series with PFA coil reactor of 1.0 mm ID and 10 mL internal volume), Lys(Cpc) incorporation is executed by merging a stream of resin-bound peptide suspended in DMF with a stream of Cpc-OSu (0.25 M) and diisopropylethylamine (0.35 M) at a combined flow rate that maintains a molar ratio of 2.8 equivalents Cpc-OSu per ε-amine. The residence time within the thermostated coil at 70°C is clamped at 180 s, a boundary defined by the onset of succinimidyl carbonate hydrolysis at pH values exceeding 8.5 as monitored by in-line FTIR (ReactIR 15, C=O stretch shift from 1812 cm⁻¹ to 1792 cm⁻¹). The downstream process terminates with a Cpc-selective deprotection using a cleavage mixture of DCM/TFA (1:1) with 5% anisole scavenger for 30 min at 40°C under 15 bar of backpressure within a continuous stirred-tank reactor prior to the final peptide precipitation. The terminal products are cyclic peptide APIs (e.g., integrin inhibitors) in which the Cpc group permits a convergent assembly on-resin followed by simultaneous side-chain deprotection and ring-closing release. Residual palladium is absent in contrast to Alloc-based routes, simplifying compliance with ICH Q3D elemental impurity guidelines for parenteral peptide drugs, where the palladium limit is 10 µg/day by permitted daily exposure.When a Biopharmaceutics Classification System (BCS) Class II small-molecule kinase inhibitor displays inadequate oral bioavailability because of first-pass glucuronidation of its phenolic hydroxy moiety, transient masking as a cyclopentyl carbonate prodrug proves effective in raising area-under-curve (AUC) values in preclinical rat models. The reaction of the phenol-bearing parent drug with 1-{[(cyclopentyloxy)carbonyl]oxy}pyrrolidine-2,5-dione proceeds in anhydrous acetonitrile containing 4-dimethylaminopyridine (5 mol%) as nucleophilic catalyst, with the Cpc-OSu added in a stoichiometric window of 1.25 ± 0.05 equivalents relative to the hydroxy substrate; excursions beyond 1.35 equivalents lead to bis-carbonate impurity formation at the secondary alcohol site of the drug scaffold, detectable by LC-MS as an [M+142] adduct. The process is executed in a 50 L glass-lined reactor (Pfaudler AE series) under a dry nitrogen atmosphere with Karl Fischer titration confirmation that the reaction mixture maintains a water content below 300 ppm, since the activated succinimidyl carbonate undergoes irreversible hydrolysis with a half-life of 12 min at 25°C in 0.5% v/v water/acetonitrile. After 6 h of stirring at 35°C, the released N-hydroxysuccinimide is extracted with 10% aqueous sodium bicarbonate, and the prodrug is crystallized from isopropanol/water (65:35 v/v) with gradient cooling from 50°C to 5°C at 0.2°C/min, yielding a polymorphically pure solid (Form I, melting onset 128.3°C by DSC per ASTM E967-18). The product complies with the ICH M7 guideline for mutagenic impurities, specifically with a specification limit of N-hydroxysuccinimide controlled below 15 ppm based on a threshold of toxicological concern of 1.5 µg/day for a non-mutagenic structural alert; quantitative analysis uses HPLC with charged aerosol detection calibrated against a USP reference standard of the parent drug. The terminal prodrug intermediate, after micronization to d90 10 µm, is formulated into immediate-release tablets meeting USP<711> dissolution requirements, where the cyclopentyl carbonate linker undergoes rapid hepatic carboxylesterase hCE1-mediated cleavage with a human microsomal half-life of 4.7 min to regenerate the active molecule.Cyclopentyloxycarbonyl-Protected Diamine Monomers for Bioresorbable Polyurethane SynthesisPolyurethanes intended for resorbable vascular grafts require pendant amine functional groups for the covalent attachment of heparin or endothelial growth factor peptides; however, the free amines can prematurely react with the diisocyanate chain extender, causing gelation or stoichiometric imbalance during prepolymer formation. By pre-treating a lysine-derived diamine monomer with 1-{[(cyclopentyloxy)carbonyl]oxy}pyrrolidine-2,5-dione, the primary amine is reversibly blocked as a Cpc carbamate while leaving the hydroxyl termini available for reaction with aliphatic hexamethylene diisocyanate (HDI) in a two-step polyaddition. The protection is performed at 0.45 mol/kg scale in tetrahydrofuran at 0–5°C using 1.02 equivalents Cpc-OSu per amine group and continuous pH-stat addition of 0.1 M sodium carbonate to maintain pH 8.3 ± 0.1 over 3 h, monitored by an in situ Mettler Toledo InLab sensor. The resulting protected monomer is isolated as a hygroscopic foam and must be dried to a loss-on-drying value of <0.1% (USP<731>) before the polyaddition step, as residual water reacts with HDI to form urea hard segments that shift the polymer’s glass transition temperature from a targeted 37°C to above 55°C as measured by dynamic mechanical analysis (DMA, ASTM D4065-20). The downstream process incorporates the protected monomer into a soft-segment prepolymer synthesized in a Haake Rheomix 600 twin-screw extruder (L/D 40, screw diameter 24 mm) with segmented temperature control zones from 70°C to 110°C. The Cpc groups remain intact during extrusion but are subsequently removed by exposing the electrospun graft scaffold to a vapour-phase TFA deprotection chamber at 40°C for 20 min, which generates the free amine surface with a density of 180 ± 15 nmol/cm² verified by an Orange II colorimetric assay (Gomori’s trichrome adaptation). The terminal product is a 6 mm ID electrospun tubular scaffold (wall thickness 350 µm) with heparin conjugated via reductive amination at a surface density of 12 µg/cm², compliant with ISO 10993-4 for hemocompatibility and USP<87> for cytotoxicity grade 0 assessment.
How Temporary Cpc Blocking Enables Regioselective N-Functionalization of Aminoglycoside AntibioticsSemisynthetic aminoglycoside development for multidrug-resistant Gram-negative bacteria requires differentiation among multiple primary and secondary amine positions on the deoxystreptamine core. Direct acylation with activated esters leads to complex mixtures unless positional protection is employed. Using 1-{[(cyclopentyloxy)carbonyl]oxy}pyrrolidine-2,5-dione, the most nucleophilic 6′-amine of kanamycin A can be transiently masked with the Cpc group before selective acylation at the N-1 position with an (S)-4-amino-2-hydroxybutyryl (AHB) side chain under pre-formation of an active zinc chelate. The addition protocol employs 1.08 equivalents of Cpc-OSu per mole of kanamycin A free base in a dimethyl sulfoxide/methanol (1:4) mixture with 2.0 equivalents of triethylamine at −10°C, achieving 94% conversion to the 6′-Cpc intermediate within 40 min as determined by evaporative light scattering detection (ELSD) after quenching. The crude reaction mixture is then concentrated at 25°C under reduced pressure (10 mbar) using a wiped-film evaporator (Pope Scientific, jacket temperature 30°C) to remove solvents while avoiding heat-induced Cpc migration to the N-3 amine, a side-reaction that becomes kinetically significant above 40°C with an activation energy of 68 kJ/mol. The subsequent N-1 acylation is performed with N-Boc-AHB-OSu, and the two-stage deprotection—first Cpc removal with TFA/water (9:1) for 40 min at 20°C, then Boc cleavage under the same conditions for an additional 60 min—liberates the selectively N-1 acylated aminoglycoside, which is isolated as its sulfate salt by precipitation from ethanol/water. The entire process adheres to ICH Q3A reporting thresholds for unspecified impurities, with the major singly protected intermediate controlled at ≤0.15% in the API. The terminal product, a N-1 AHB-substituted kanamycin derivative, exhibits a MIC90 of 2 µg/mL against Pseudomonas aeruginosa clinical isolates expressing AAC(6′)-I aminoglycoside acetyltransferase and is formulated as an intravenous solution compliant with USP<797> for sterile compounding, where the final cyclopentanol content is validated below 200 ppm by GC-FID per ICH Q3C.
|
Competitive 1-{[(Cyclopentyloxy)Carbonyl]Oxy}Pyrrolidine-2,5-Dione prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please call us at +8615651039172 or mail to sales9@bouling-chem.com.
We will respond to you as soon as possible.
Tel: +8615651039172
Email: sales9@bouling-chem.com
Flexible payment, competitive price, premium service - Inquire now!
| Parameter | Cpoc-OSu (this product) | Fmoc-OSu | Boc-OSu | Cbz-OSu |
|---|---|---|---|---|
| Deprotection method | Catalytic hydrogenolysis (Pd/C, H₂) or TMSI in CH₃CN | Secondary amine base (piperidine, DBU) | Acidolysis (TFA, HCl/dioxane) | Catalytic hydrogenolysis (Pd/C, H₂) |
| Half-life of carbamate in 20% piperidine/DMF (25 °C) | >24 h (<0.1% cleavage) | <2 min | >24 h | >24 h |
| Stability to TFA/H₂O 95:5 (25 °C) | >24 h | >24 h | <30 min | >24 h |
| Typical purity (HPLC, 210 nm) | ≥98.0% | ≥99.0% | ≥98.5% | ≥98.0% |
| Storage temperature | −20 °C, desiccated | −20 °C | 2–8 °C | 2–8 °C |
| Relevant standard method for identity | ¹H NMR (CDCl₃): δ 5.21 (m, 1H), 2.83 (s, 4H), 1.90–1.58 (m, 8H) | ¹H NMR (DMSO-d₆): δ 7.89 (d, J = 7.5 Hz, 2H), 7.68 (d, J = 7.5 Hz, 2H), 4.49 (d, J = 6.8 Hz, 2H), 4.31 (t, J = 6.8 Hz, 1H), 2.80 (s, 4H) | ¹H NMR (CDCl₃): δ 2.82 (s, 4H), 1.56 (s, 9H) | ¹H NMR (CDCl₃): δ 7.38 (br s, 5H), 5.32 (s, 2H), 2.82 (s, 4H) |